Irritable bowel syndrome (IBS) is associated with alterations of gut microbiota, highlighting its importance in the disease onset or evolution. Animal models are commonly used in preclinical phases to study therapeutic strategies for IBS, but this approach remains limited by main differences between human and animal digestive physiology, including gut microbiota. In vitro digestion models can offer a great alternative to in vivo assays to perform mechanistic studies. However, there is no relevant in vitro system reproducing the colonic environment of IBS patients. In this context, an in-depth literature review was performed to adapt the mucosal Artificial Colon (M-ARCOL) model to the specific conditions found in diarrheic IBS (IBS-D) patients. This in vitro model reproduces both the physicochemical (pH, temperature, transit time, nutrient availability and anaerobiosis) and microbial (luminal and mucus-associated microbiota) parameters of the human colonic environment, though inoculation with faecal samples. One stool was used to inoculate two bioreactors ran in parallel, one set-up with healthy conditions, the other with IBS-D parameters (n=4). Samples were regularly collected to evaluate gut microbiota composition (qPCR and 16S sequencing) and metabolic activity (gas and short chain fatty acid production). In IBS-D condition, a tendency to produce less SCFAs and energy was shown. A decrease in Archaea and Ruminococcaceae, together with an increase in Akkermansia, Veillonellaceae and Proteobacteria was observed in accordance with in vivo data. This study brings first evidence that reproducing physicochemical parameters of IBS-D colon was sufficient to induce shift in microbiota structure, close to the in vivo situation. In a next step, the development of the dysbiotic model will be performed by inoculating bioreactors with stool samples from IBS-D patients. Once fully validated, this in vitro model may help to test strategies aiming to restore gut microbiota eubiosis such as pre- or probiotics supplementation or faecal microbiota transplantation.